Lightlake Therapeutics Inc.
OTC Bulletin Board : LLTP

Lightlake Therapeutics Inc.

February 24, 2011 09:21 ET

Lightlake Therapeutics Appoints Professor Martin Wilkins Medical Advisor

LONDON, ENGLAND--(Marketwire - Feb. 24, 2011) - Lightlake Therapeutics Inc. ("Lightlake") (OTCBB:LLTP) is pleased to announce the appointment of Professor Martin Wilkins as Medical Advisor, as Lightlake continues to build a world-class advisory panel.

Martin R. Wilkins is the Professor of Clinical Pharmacology and Head of the Division of Experimental Medicine, Imperial College London and Director of Clinical and Investigative Sciences within Imperial College Healthcare NHS Trust. He is a Consultant Physician within Imperial College Healthcare NHS Trust and has been the Director of the Sir John McMichael Centre for Clinical Research at Hammersmith Hospital since its establishment in 2001.

Professor Wilkins is a clinician scientist with a background in clinical pharmacology and toxicology. His primary interest is in proof-of-concept studies in humans.

He directs an internationally competitive research program in pulmonary hypertension from basic science to clinical trials, publishing regularly in peer-reviewed journals. His work is funded by grants from the Wellcome Trust, Medical Research Council and The British Heart Foundation.

The Division of Experimental Medicine hosts the Wellcome Trust – GSK Translational Medicine Fellowship Programme at Imperial College.

Dr Michael Sinclair, Chairman of Lightlake Therapeutics commented: 'Professor Wilkins brings the ability to bridge the gap between academic studies, and clinical development.' 

'He leads a unit with an international reputation, within a world-class institution, which will be one of the main centres for our Phase III trial.'

About Lightlake Therapeutics

Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be completed during 2011. 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "could", "would", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "projects", "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact Information


Keyword Cloud

View Website